GlassScriptPhysician profile
Amy Riordan
NPI 1497121552
$2,384.41
in general payments reported to CMS, 2019-2025
31 companies · $672 in 2025
The $672 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $417 · 2022: $609 · 2023: $201 · 2024: $485 · 2025: $672.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $777.67 | 2021-2025 | |
| Novo Nordisk INC | $432.41 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $216.16 | 2021-2025 | Evenity, Otezla, Repatha |
| Glaxosmithkline, LLC. | $83.00 | 2021-2023 | Arexvy |
| Astrazeneca Pharmaceuticals LP | $81.56 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $81.09 | 2021-2025 | Kisunla, Mounjaro, Zepbound |
| Pfizer INC. | $72.14 | 2023-2025 | |
| Currax Pharmaceuticals LLC | $56.46 | 2021-2022 | |
| Philips North America LLC | $50.55 | 2021 | |
| Esperion Therapeutics, INC. | $44.41 | 2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.11 | 2022-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $42.33 | 2021 | |
| Phadia US INC. | $39.66 | 2025 | Immunocap |
| Biohaven Pharmaceutical Holding Company LTD. | $39.57 | 2022 | |
| Exact Sciences Corporation | $33.57 | 2023-2025 | Cologuard Collection Kit |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $31.55 | 2022-2024 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $27.91 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.36 | 2022 | |
| Merck Sharp & Dohme LLC | $26.53 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.53 | 2025 | |
| Sumitomo Pharma America, INC. | $17.75 | 2025 | Gemtesa |
| Actelion Pharmaceuticals US, INC. | $16.34 | 2025 | Uptravi, Opsumit |
| Lundbeck LLC | $14.91 | 2025 | Rexulti |
| Depuy Synthes Sales INC. | $14.62 | 2024 | Orthovisc, Peak, Monovisc |
| Daiichi Sankyo INC. | $14.14 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.81 | 2021 | |
| Medtronic, INC. | $13.50 | 2024 | Closurefast |
| Sanofi Pasteur INC. | $13.18 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $13.18 | 2021 | |
| Astellas Pharma US INC | $12.75 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Riordan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.